Table II.
Groups | Bcl-2 positive cells | Bcl-2 mRNA | Bcl-2 |
---|---|---|---|
Control group | 23.197±2.726 | 0.440±0.076 | 0.349±0.049 |
Model group | 29.606±2.143a | 0.605±0.051a | 0.508±0.044a |
rHuEpo treated group | 42.639±1.829a–c | 0.984±0.019a–c | 0.791±0.045a–c |
LY294002 treated group | 35.415±2.011a,b | 0.843±0.034a,b | 0.636±0.021a,b |
LY294002 control group | 41.060±0.476a–c | 0.981±0.021a–c | 0.762±0.050a–c |
F-value | 19.27 | 27.95 | 18.07 |
P-value | <0.05 | <0.05 | <0.05 |
P<0.05, control group vs. model group, rHuEpo treated, LY294002 treated, LY294002 control groups
P<0.05, model group vs. rHuEpo treated, LY294002 treated, LY294002 control groups
P<0.05, LY294002 treated group vs. rHuEpo treated, LY294002 control groups. No significant difference was found between rHuEpo treated group and LY294002 control group. rHuEpo, recombinant human erythropoietin.